Trickey A, Nixon E, Christensen H, Finn A, Thomas A, Relton C, Montgomery C, Hemani G, Metz J, Walker JG, Turner K, Kwiatkowska R, Sauchelli S, Danon L, Brooks-Pollock E. University students and staff able to maintain low daily contact numbers during various COVID-19 guideline periods. Epidemiol Infect. 2021 Aug 10;149:e169. doi: 10.1017/S0950268821001618
Fan W-Y, Fleming A, Robertson G, Uji A, van Hemert J, Singer M, Sagong M, Ip M, Sadda SR. Fractal analysis of retinal vasculature in normal subjects on ultra-wide field fluorescein angiography. Int J Ophtalmol. 2020 Jul 18;13(7):1109-14. doi: 10.18240/ijo.2020.07.15
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Musetti S, Huang L. Nanoparticle-mediated remodeling of the tumor microenvironment to enhance immunotherapy. ACS Nano. 2018 Dec 26;12(12):11740-55. doi: 10.1021/acsnano.8b05893
Wasserman M, Lucas A, Jones D, Wilson M, Hilton B, Vyse A, Madhava H, Brogan A. Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK. Epidemiol Infect. 2018 Oct;146(14):1797-806. doi: 10.1017/S095026881800198X
Kamptner NL, Teyber FH, Rockwood NJ, Drzewiecki D. Evaluating the efficacy of an attachment-informed psychotherapeutic program for incarcerated parents. J Prison Educ Reentr. 2017 Dec;4(2):62-81.
Buck PO, Meyers JL, Gordon LD, Parikh R, Kurosky SK, Davis KL. Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease in the USA: an analysis of administrative claims. Epidemiol Infect. 2017 Jul;145(10):2109-21. doi: 10.1017/S0950268817000887.
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Poulos C, Riewpaiboon A, Stewart JF, Clemens J, Guh S, Agtini M, Sur D, Islam Z, Lucas M, Whittington D. Costs of illness due to endemic cholera. Epidemiol Infect. 2012 Mar 1;140(03):500-9.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.